Personalized Medicine – News and Features

Jakub Vašíček joined us to discuss a new bioinformatic tool – ProHap – a Python-based tool that creates custom protein sequence databases from large panels of reference human haplotypes.

UK Biobank's proteomics study will measure 5,400 proteins in 600,000 samples, tracking changes over mid-to-late life. By combining genetic, imaging and proteomic data, this initiative promises breakthroughs in disease diagnosis and drug discovery.

This article provides examples of how AI is helping to shape drug discovery, from drug design through to clinical trials.

Researchers developed a computational model to optimize drug selection for chronic myelogenous leukemia (CML), tailoring treatment to individual patients. The model predicts responses to tyrosine kinase inhibitors, reducing resistance.

A first-of-its-kind AI platform could help clinicians assess whether an individual will benefit from a particular therapy in clinical trials.

A new study has outlined the first genomic evidence of early migration from New Guinea into the Wallacea, an archipelago containing Timor-Leste and hundreds of inhabited eastern Indonesian islands.

A new method using cell-type-specific epigenetic clocks measures biological aging in neurons, glia and liver cells, revealing rapid aging in Alzheimer's and liver diseases. This tool improves understanding of aging-related diseases.

Oleanolic acid, found in grapes, could increase the effectiveness of chemotherapy, reducing the amount of drug needed.

This article examines some of the latest advances in biomarker discovery in the fields of cancer and neurodegenerative and infectious diseases and the technologies that are driving these discoveries.

Weill Cornell researchers found that prostate cancer reprograms androgen receptors, shifting their role from growth inhibition to promotion. This mechanism drives tumor development. Their findings identify genes that suppress cancer growth.